Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
July 09, 2018 08:00 ET
|
Retrotope
LOS ALTOS, Calif. and LOS ANGELES, July 09, 2018 (GLOBE NEWSWIRE) -- Retrotope and collaborators led by Dr. Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology, and Interim...
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
June 28, 2018 08:00 ET
|
Retrotope
Patient enrollment anticipated to start in July 2018 LOS ALTOS, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration (FDA) has granted the...
Retrotope Announces the Initiation of Expanded Access (Compassionate Use) Trials of RT001 in Two Neurodegenerative Disorders
June 11, 2018 08:00 ET
|
Retrotope
LOS ALTOS, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today the start of two single-patient, Compassionate Use trials of RT001 at major university medical centers in Late Onset...
Retrotope Announces RT001 Clinical Data Presentation at the 2018 American Academy of Neurology (AAN) Annual Meeting
April 24, 2018 08:00 ET
|
Retrotope
Positive Findings from Compassionate Use Study in Patient with Infantile Neuroaxonal Dystrophy (INAD) Presented LOS ALTOS, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today...
Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia
April 18, 2018 08:00 ET
|
Retrotope
Protocol for Pivotal Clinical Trial Has Been Submitted to the US FDA LOS ALTOS, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today peer-reviewed publication of positive Phase...
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration
November 02, 2017 09:00 ET
|
Retrotope
LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...
Study of Retrotope’s deuterated polyunsaturated fatty acid drugs published in The FEBS Journal
October 30, 2017 09:00 ET
|
Retrotope
LOS ALTOS, Calif. and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Retrotope and collaborators, led by Dr. Brian Bennett of Queen’s University, have published a paper entitled “Deuterium-reinforced...